This study provides valuable evidence for clinical decision-making by demonstrating the effectiveness and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP-4) inhibitors in older adults with type 2 diabetes. The findings support SGLT2 inhibitors as a favorable treatment option, offering improved glycemic control and potentially reduced risk of adverse cardiovascular events when compared to DPP-4 inhibitors in this population. Here, SLC5A2 is linked to type 2 diabetes mellitus.